Viking Therapeutics
9920 Pacific Heights Blvd, Suite 350
San Diego
California
92121
United States
Tel: 858-550-7810
Website: http://www.vikingtherapeutics.com/
Email: info@vikingtheraputics.com
218 articles about Viking Therapeutics
-
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
4/17/2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.
-
Metabolic dysfunction-associated steatohepatitis experts welcomed Madrigal’s Rezdiffra as an “important first," but there are more mid- to late-stage therapies showing promising results.
-
GLP-1 treatments are all the rage in this space, but they aren’t the only approach in development. The pipeline assets highlighted here offer a differentiated approach, potentially increasing efficacy or reducing side effects.
-
Now in Phase III with its small molecule orforglipron, Eli Lilly is leading the oral GLP-1 race against Novo Nordisk, Pfizer, Roche and others.
-
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
3/26/2024
Viking Therapeutics, Inc. announced positive results from the company's Phase 1 multiple ascending dose clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, in development for the potential treatment of metabolic disorders such as obesity.
-
The early-stage study showed that Viking Therapeutics’ oral obesity candidate VK2735, a dual agonist of the GLP-1 and GIP receptors, elicited a 3.3% reduction in mean body weight. The company plans to start a Phase II trial.
-
The recent FDA decision will likely mean more Medicare patients gain access to the blockbuster weight loss drug, experts say. Meanwhile, results continue to roll in for GLP-1 agonists for conditions beyond diabetes and obesity.
-
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
3/4/2024
Viking Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 7,441,650 shares of its common stock at a price to the public of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 970,650 additional shares of common stock.
-
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
2/29/2024
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the pricing of its underwritten public offering of 6,471,000 shares of its common stock at a price to the public of $85.00 per share.
-
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
2/27/2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) today announced positive top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity.
-
Viking Therapeutics announced Tuesday that its GLP-1/GIP receptor dual agonist helped patients lose up to nearly 15% of their weight over about three months in a Phase II study.
-
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
2/7/2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on its clinical pipeline and other corporate developments.
-
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
1/31/2024
Viking Therapeutics, Inc. announced that the company will release financial results for the fourth quarter and year-end 2023 after the market close on Wednesday, February 7, 2024.
-
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023
11/13/2023
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).
-
Viking Therapeutics to Participate at Upcoming November 2023 Investor Conferences
11/2/2023
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate at several upcoming investor conferences.
-
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
10/25/2023
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) today announced its financial results for the third quarter and nine months ended September 30, 2023, and provided an update on its clinical pipeline and other corporate developments.
-
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
10/23/2023
Viking Therapeutics, Inc. today announced the completion of patient enrollment in its Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
-
The non-alcoholic steatohepatitis space is still a “big mystery,” analysts tell BioSpace, but its connection to weight loss could provide an additional opportunity for contenders.
-
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
10/18/2023
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2023 after the market close on Wednesday, October 25, 2023.
-
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
10/17/2023
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX) today announced that new results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were featured in an oral presentation at ObesityWeek 2023, the annual meeting of The Obesity Society.